K2 Principal Fund’s Alexion Pharmaceuticals ALXN Stock Holding History

K2 Principal Fund’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$1.53M	–	498
2021 Q1	$1.53M	Buy	+10,000	New	+$1.55M	0.12%	183

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

K2 Principal Fund's ALXN Position: Q3 2021 in Review

K2 Principal Fund sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 34,777 shares — an estimated $6.39M sold.

K2 Principal Fund first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $6.39M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

K2 Principal Fund reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
K2 Principal Fund sold 34,777 Alexion Pharmaceuticals shares in Q3 2021, an estimated $6.39M.
K2 Principal Fund first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
K2 Principal Fund's Alexion Pharmaceuticals position peaked at $6.39M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on K2 Principal Fund's 13F filing for Q3 2021, filed 12 Nov 2021.